PHARMAC has made a decision to make changes to the funding of rituximab, including widening access and changing brands.
PHARMAC is pleased to announce a decision to widen access to bortezomib for patients with multiple myeloma and amyloid light-chain (AL) amyloidosis in conjunction with a change of funded brand of bortezomib through PHARMAC’s annual tender process.
PHARMAC is pleased to announce a decision to fund two new cancer treatments and amend the contractual arrangements for one currently funded treatment through an agreement with AstraZeneca Pty Ltd.
Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year.
Response to a request for information about the MMR vaccine.
Response to a request for information about sex change treatments.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender dated 1 November 2018.
PHARMAC is seeking your feedback on the proposal to make changes to the funded brands of labetalol tablets, which are used in the treatment of hypertension in pregnancy.
Closes: 4pm, Monday 16 December 2019.
Response to an Official Information Act request for data on cefuroxime.
PHARMAC is seeking feedback on a proposal relating to how we fund discarded medicines (“wastage”) in community pharmacies.
Closes: 5 pm on Friday, 20 December 2019.
Response to an Official Information Act request on prescription numbers.
Response to an Official Information Act request for information on asthma inhalers
Response to an Official Information Act request for data on chloramphenicol (Chlorsig).
Response to a request for information on the supply of phenelzine.
PHARMAC has made a decision to make changes to the criteria for funding of amino acid infant formula (AAF) from 1 July 2020. AAF (brand names Alfamino Junior, Elecare and Neocate) is used as a milk substitute in infants who have an allergy or severe intolerance to cow’s milk and cannot take other funded milk substitutes.
Response to an Official Information Act request for NPPA applications for venlafaxine and lamotrigine.
Response to a request for information on use of specific cancer drugs.
Patients taking lamotrigine who have concerns about the change can talk with their doctor about remaining on their current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
PHARMAC invites proposals for the supply of dental and oral health products to New Zealand District Health Board (DHB) hospitals and their associated community settings.
All proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4pm NZT Thursday 19 March 2020 - RFx ID 21609822.
If you have any questions about this RFP, please post these on the Government Electronic Tenders Service (www.gets.govt.nz).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this RFP to be kept up to date.
Proposal to change the sole subsidised brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe
PHARMAC is seeking your feedback on a proposal to make changes to the funded brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe.
Closes: 4 pm on Thursday, 28 November 2019.